Sugi Predict

Sugi Predict / Targets / SLC2A9

SLC2A9

Solute carrier family 2, facilitated glucose transporter member 9 · Q9NRM0 · SLC2A9 on Sugi Atlas →

1,176 patent compounds predicted against SLC2A9, 952 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1299461 SCHEMBL1299461 0.75 3/20
SCHEMBL843208 SCHEMBL843208 0.71 3/20
Lesinurad Lesinurad (SCHEMBL1299308) 0.69 3/20
Lesinurad Lesinurad (SCHEMBL1299973) 0.69 3/20
SCHEMBL1299370 SCHEMBL1299370 0.69 3/20
Lesinurad Lesinurad (SCHEMBL842962) 0.69 3/20
Lesinurad Lesinurad (SCHEMBL2221210) 0.68 3/20
SCHEMBL1299832 SCHEMBL1299832 0.68 3/20
Lesinurad Lesinurad (SCHEMBL2265513) 0.68 3/20
SCHEMBL4735350 SCHEMBL4735350 0.68 3/20
SCHEMBL16500465 SCHEMBL16500465 0.68 3/20
SCHEMBL249022 SCHEMBL249022 0.67 3/20
SCHEMBL1299492 SCHEMBL1299492 0.67 3/20
SCHEMBL15698391 SCHEMBL15698391 0.67 3/20
SCHEMBL248867 SCHEMBL248867 0.66 3/20
SCHEMBL249261 SCHEMBL249261 0.66 3/20
SCHEMBL1300691 SCHEMBL1300691 0.66 3/20
SCHEMBL4735395 SCHEMBL4735395 0.66 3/20
SCHEMBL13569386 SCHEMBL13569386 0.66 3/20
SCHEMBL12056227 SCHEMBL12056227 0.65 3/20

Clinical trials — most relevant to SLC2A9 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation. PHASE4COMPLETED
Effect of Anti-diabetic Drugs on Glycemic Variability PHASE4COMPLETED
Dapagliflozin Effect on Erythropoiesis and Physical Fitness PHASE4WITHDRAWN
Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration PHASE4COMPLETED
The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients PHASE4COMPLETED
Reformulated F75 Milk to Treat Severe Acute Malnutrition PHASE2/PHASE3COMPLETED
Empagliflozin in Hypertrophic Cardiomyopathy PHASE3ACTIVE_NOT_RECRUITING
Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin PHASE2NOT_YET_RECRUITING
Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes PHASE2COMPLETED
PK and PD of YG1699 in CKD Patients With Diabetes PHASE1NOT_YET_RECRUITING
Multi-Tracer PET Assessment of Primary Brain Tumors PHASE1COMPLETED
Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans PHASE1COMPLETED
Sodium Lactate Infusion in GLUT1DS Patients EARLY_PHASE1COMPLETED
Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I EARLY_PHASE1COMPLETED
A Proof-of-concept Study Evaluating the Microbiota-gut-brain Axis nanRECRUITING
Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients nanCOMPLETED
Clinical Utility of Breath Tests in GI nanCOMPLETED
Red Blood Cell Exchange Transfusion as a Novel Treatment for GLUT1 Deficiency Syndrome nanSUSPENDED
Characterization of Abdomino-pelvic Lesions by 18Fluorine- Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography nanNOT_YET_RECRUITING
Harmonic Ratio in Patients With GLUT1 Deficiency Syndrome nanACTIVE_NOT_RECRUITING
Impact of Sodium Glucose Co-transporter 2-Inhibitors on Clinical Outcome and Left Ventricular Function in Patients Presented by Acute Myocardial Infarction nanCOMPLETED
SLC2A1 Variants and Diabetic Nephropathy nanCOMPLETED
Metabolic and Hemodynamic Effects of the Inhibitors of Type 2 Sodium Glucose Co-transporters (ISGLT2) in Diabetic Patients With Heart Failure nanCOMPLETED
Dual PETOvac - Dual Time PET/CT in the Preoperative Assessment of Ovarian Cancer nanUNKNOWN
The Effect of Artificial Sweeteners on Blood Glucose Response nanWITHDRAWN
The Effect of a Diet Based on Low Sodium and Slowly Absorbed Carbohydrates on the Incidence of Refeeding Syndrome in Patients With Head and Neck Cancer nanCOMPLETED
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients. nanRECRUITING
The Effect of Green Coffee Extract on Blood Glucose Homeostasis in Healthy Adults nanCOMPLETED
Hepatic Substrate Flux Rates in Type 2 Diabetes nanACTIVE_NOT_RECRUITING
Genetic Variation in CLTCL1 and Whole-body Glucose Control nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC2A9 binder may also engage these)

ProteinNameSimilarity
Q3T9X0 — 1.000 Q3T9X0 →
Q5RB09 — 0.989 Q5RB09 →
Q8IZD6 — 0.953 Q8IZD6 →
Q504N2 — 0.949 Q504N2 →
Q78KK3 — 0.933 Q78KK3 →
Q9P290 — 0.923 Q9P290 →
SLC67A1 Solute carrier family 22 member 18 0.916 landscape →
Q3SZQ2 — 0.915 Q3SZQ2 →
Q3UHH2 — 0.915 Q3UHH2 →
Q6ZW05 — 0.913 Q6ZW05 →
Q9QZG1 — 0.910 Q9QZG1 →
Q91VM4 — 0.906 Q91VM4 →
SPNS2 Sphingosine-1-phosphate transporter SPNS2 0.906 landscape →
SLC16A3 Monocarboxylate transporter 4 0.906 landscape →
QRFPR Pyroglutamylated RF-amide peptide receptor 0.904 landscape →
B9EKX1 — 0.904 B9EKX1 →
Q8VCV9 — 0.903 Q8VCV9 →
GALR1 Galanin receptor type 1 0.903 landscape →
Q2M3R5 — 0.903 Q2M3R5 →
Q6AY78 — 0.903 Q6AY78 →
P57787 — 0.903 P57787 →
O09014 — 0.903 O09014 →
O15375 — 0.903 O15375 →
Q27963 — 0.902 Q27963 →
A1A5C7 — 0.901 A1A5C7 →
P24053 — 0.901 P24053 →
Q62805 — 0.900 Q62805 →
Q91W98 — 0.900 Q91W98 →
Q5VZY2 — 0.900 Q5VZY2 →
Q96SL1 — 0.899 Q96SL1 →